Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026, and will host a conference call with a Q&A session at 8:30 a.m. Eastern Time. Investors can join via toll-free and international dial-in numbers or through a live webcast.

Market Reaction – PTHS

+1.18% $27.25 3.5x vol

15m delay

+1.18% Vs previous close

+2.7% Peak in 19 min

$27.25 Last Price

$25.79 $29.01 Day Range

$92.31M Market Cap

3.5x Rel. Volume

Following this news, PTHS has gained 1.18%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.7% during the session. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $27.25. Trading volume is very high at 3.5x the average, suggesting strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

Recent insider activity was classified as Net Buying, with 35,948 shares bought and 2,424 sold over ...

Analysis

Recent insider activity was classified as Net Buying, with 35,948 shares bought and 2,424 sold over 90 days. The platform context also includes an effective S-3 shelf, making financing disclosures a relevant risk to monitor.

Key Figures

Results Report Date: August 13, 2026 Conference Call Time: 8:30 a.m. Eastern Time

2 metrics

Results Report Date August 13, 2026 Second quarter 2026 financial results

Conference Call Time 8:30 a.m. Eastern Time Call and question-and-answer period

Previous Earnings date Reports

2 past events · Latest: May 01 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 01	Earnings-date notice	Neutral	+0.0%	Scheduled Q1 2026 results report and 8:30 a.m. conference call
Mar 09	Earnings-date notice	Neutral	-0.3%	Scheduled Q4 and full-year 2025 results report and conference call

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two tag-specific earnings-date events recorded price reactions of 0% and -0.3%, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to hold a conference call at 8:30 a.m. ET

DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern Time.

Details for the conference call can be found below:
Date:	Thursday, August 13, 2026
Time:	8:30 a.m. Eastern Time
Toll Free:	1-877-451-6152
International:	1-201-389-0879
Conf.ID:	13761132

Call.Me: Participants can use the dial-in numbers above or click the CallMe link for instant telephone access to the event. The CallMe link will be activated 15 minutes prior to the scheduled call start time.

Webcast: Participants can also join via the web at https://viavid.webcasts.com/starthere.jsp?ei=1767131&tp_key=12eae87cb3

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE® (abametapir), a topical treatment for head lice. More information is available at https://pelthos.com/. Follow Pelthos on LinkedIn and X.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

When will Pelthos Therapeutics (PTHS) report Q2 2026 financial results?

Pelthos Therapeutics will report its second quarter 2026 financial results on Thursday, August 13, 2026. According to Pelthos, the announcement will be accompanied by a conference call and Q&A session for investors and analysts.

What time is the Pelthos Therapeutics (PTHS) Q2 2026 earnings conference call?

The Pelthos Therapeutics Q2 2026 conference call is scheduled for 8:30 a.m. Eastern Time on August 13, 2026. According to Pelthos, the call will include prepared remarks followed by a question-and-answer period.

How can investors join the Pelthos Therapeutics (PTHS) Q2 2026 earnings call by phone?

Investors can join by dialing 1-877-451-6152 toll-free or 1-201-389-0879 internationally using conference ID 13761132. According to Pelthos, a CallMe link will also provide instant telephone access shortly before the call.

Is there an online webcast for the Pelthos Therapeutics (PTHS) Q2 2026 earnings call?

Yes, Pelthos offers a webcast for the Q2 2026 earnings call at https://viavid.webcasts.com/starthere.jsp?ei=1767131&tp_key=12eae87cb3. According to Pelthos, participants may choose either the webcast or telephone dial-in to access the event.

What is the CallMe feature for the Pelthos Therapeutics (PTHS) August 13, 2026 conference call?

The CallMe feature allows participants to access the earnings call via an instant callback link instead of manual dialing. According to Pelthos, the CallMe link activates 15 minutes before the scheduled 8:30 a.m. Eastern Time start.